Cue Biopharma, Inc. earnings per share and revenue
On 12 nov. 2025, CUE reported earnings of -0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 25.77% surprise. Revenue reached 2.15 million, compared to an expected 2.31 million, with a -7.07% difference. The market reacted with a -7.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analystes forecast an EPS of -0.10 USD, with revenue projected to reach 2.52 million USD, implying an hausse of 42.86% EPS, and hausse of 17.50% in Revenue from the last quarter.
FAQ
What were Cue Biopharma, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cue Biopharma, Inc. reported EPS of -$0.07, beating estimates by 25.77%, and revenue of $2.15M, -7.07% below expectations.
How did the market react to Cue Biopharma, Inc.'s Q3 2025 earnings?
The stock price moved down -7.19%, changed from $0.67 before the earnings release to $0.62 the day after.
When is Cue Biopharma, Inc. expected to report next?
The next earning report is scheduled for 30 mars 2026.
What are the forecasts for Cue Biopharma, Inc.'s next earnings report?
Based on 3
analystes, Cue Biopharma, Inc. is expected to report EPS of -$0.10 and revenue of $2.52M for Q4 2025.